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Available online 29 March 2017The neuronal ceroid lipofuscinoses are a group of recessively inherited, childhood-onset neurodegenerative con-
ditions. Several forms are caused bymutations in genes encodingputative lysosomalmembrane proteins. Studies
of the cell biology underpinning these disorders are hampered by the poor antigenicity of the membrane pro-
teins, which makes visualization of the endogenous proteins difﬁcult. We have used Drosophila to generate
knock-in YFP-fusions for two of the NCL membrane proteins: CLN7 and CLN3. The YFP-fusions are expressed at
endogenous levels and the proteins can be visualized live without the need for overexpression. Unexpectedly,
both CLN7 and CLN3 have restricted expression in the CNS of Drosophila larva and are predominantly expressed
in the glia that form the insect blood-brain-barrier. CLN7 is also expressed inneurons in the developing visual sys-
tem. Analogous with murine CLN3, Drosophila CLN3 is strongly expressed in the excretory and osmoregulatory
Malpighian tubules, but the knock-in also reveals unexpected localization of the protein to the apical domain ad-
jacent to the lumen. In addition, some CLN3 protein in the tubules is localized within mitochondria. Our in vivo
imaging of CLN7 and CLN3 suggests new possibilities for function and promotes new ideas about the cell biology
of the NCLs.
© 2017 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY license (http://
creativecommons.org/licenses/by/4.0/).Keywords:
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Drosophila1. Introduction
The neuronal ceroid lipofuscinoses (NCLs) are a collection of
inherited neurodegenerative lysosomal storage disorders predominant-
ly affecting children (Jalanko and Braulke, 2009). They share symptoms
that include visual failure, seizures, psychiatric and behavioral changes
and a progressive decline in mental and motor functions followed by
premature death. The NCLs have a common histopathological hallmark:
accumulation of autoﬂuorescent lysosomal storage material in most
cells, including neurons, indicative of lysosomal dysfunction or failure.
Another common histopathological feature of the disorders is an early
glial activation, which precedes selective neuronal loss (reviewed in
Cooper et al., 2015).
The NCLs are recessively inherited monogenic disorders (with the
exception of one rare adult-onset autosomal dominant form). To date
mutations have been identiﬁed in 14 genes responsible for NCL with
varying ages of onset. These encode soluble intra-lysosomal proteins
and enzymes (CLN1, CLN2, CLN5, CLN10 and CLN13), late endosomal/orth@bham.ac.uk
ect.com).
. This is an open access article underlysosomal transmembrane proteins (CLN3, CLN7 and CLN12), ER/
ERGIC membrane proteins (CLN6 and CLN8), cytosolic proteins (CLN4
and CLN14) and an extracellular protein (CLN11) (reviewed in Carcel-
Trullols et al., 2015). The cell biology underpinning the NCLs is not
well understood despite many years of study, nor is it clear why pathol-
ogy is almost entirely restricted to the CNS despite many of the CLN
genes beingwidely expressed. We have turned to the fruit ﬂy, Drosoph-
ila, to study two of the CLN genes encoding putative lysosomal mem-
brane transporters, CLN7 and CLN3. Drosophila expresses only a subset
of the CLN genes and we hypothesized that these are likely to have
core functions conserved in vertebrates.
Mutations in CLN7/MFS-domain containing 8 (CLN7/MFSD8) are re-
sponsible for late-infantile onset NCL (or CLN7 disease), with disease
onset at 1.5–5 years of age (Kousi et al., 2009). The CLN7 protein is pre-
dicted to be a member of the multi-facilitator superfamily of trans-
porters, each of which has twelve membrane spanning domains
(Siintola et al., 2007). However, its function and any possible substrate
it may transport remains unknown. In cell culture experiments with
tagged forms, CLN7 protein is localized primarily in lysosomes (Shariﬁ
et al., 2010; Siintola et al., 2007; Steenhuis et al., 2010) and has been
identiﬁed by lysosomal proteomics (Chapel et al., 2013). Consistent
with this, phenotypes inmutantmice suggest a role for CLN7 in autoph-
agy (Brandenstein et al., 2016). In a related project that will be reportedthe CC BY license (http://creativecommons.org/licenses/by/4.0/).
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tant Drosophila (O'Hare, Mohammed, Tuxworth and Tear, in prep).
Mutations in the CLN3 gene lead to Juvenile NCL, the most common
form of NCL (also known as Batten disease or CLN3 disease) with onset
usually at 5–7 years of age (Lerner et al., 1995). The CLN3 gene is pre-
dicted to encode a hydrophobic six transmembrane domain protein
(Ratajczak et al., 2014) and is conserved in many species including
yeast and Drosophila but its function is unclear despite more than
20 years of study. Various studies of CLN3 in different cell lines and
models have suggested roles in regulation of lysosomal pH, anterograde
and retrograde post-Golgi trafﬁcking, autophagy, endocytosis, apopto-
sis, oxidative stress responses or Notch and JNK signalling (Tuxworth
et al., 2011; Tuxworth et al., 2009 and reviewed in Carcel-Trullols et
al., 2015). The expression pattern of the CLN3 gene in mice is known
from a combination of in situ hybridization studies and a knock-in re-
porter of gene expression (Ding et al., 2011; Eliason et al., 2007). The
knock-in mouse, in particular, demonstrated an expression pattern in
the CNS predominantly in the later stages of embryonic development
and persisting in post-natal development. Interestingly, strong expres-
sion from early stages of development in the endothelia of the brain
was maintained into adult life (Eliason et al., 2007). CLN3 expression
was also detected in endothelia in other organs, in epithelia and strong-
ly in the renal tubules, where its expression is regulated by osmolality
(Stein et al., 2010). Taken together, these data suggest an important
role for CLN3 in epithelia but since the reporter used was a nuclear-lo-
calized β-galactosidase, the sub-cellular localization of CLN3 protein in
polarized epithelial cells could not be determined. CLN3 is considered
primarily a lysosomal protein, based on numerous studies in cell culture
with epitope-tagged or ﬂuorescent fusion proteins (reviewed in Phillips
et al., 2005) and it has been identiﬁed in lysosomal membranes by pro-
teomics (Chapel et al., 2013). Studies of mammalian CLN3 localization
have generally relied on overexpression; oneof the fewstudies to detect
endogenous CLN3 indicated a mitochondrial localization in Müller glia
of the mouse retina and in the inner segments of photoreceptors (Katz
et al., 1997). Knock-in approaches have been used in yeast to avoid
overexpression artefacts and reveal CLN3 can be found in the Golgi
(Kama et al., 2011) or at the vacuole (the yeast lysosomal equivalent)
with sub-cellular localization regulated by intracellular pH (Wolfe et
al., 2011). In Dictyostelium, GFP-CLN3 expressed at low levels localizes
to the osmoregulatory contractile vacuole and other endocytic vesicles
(Huber et al., 2014) but knock-in approaches have not been used to
date to study CLN3 in a species with a complex nervous system.
The lack of reagents for reliable detection of endogenous protein lo-
calization in vivo for either CLN7 or CLN3 has hampered the search for
their functions. To overcome these limitations, we used recombineering
and CRISPR/Cas9 genome editing to generate seamless knock-in YFP fu-
sions of CLN7 and CLN3 to report gene expression and protein localiza-
tion in Drosophila. We show that CLN7 is strongly expressed in glial
cells in the CNS but largely absent fromneurons other than in the devel-
oping visual system. CLN3 is also expressed in glia and very strongly in
Malpighian tubules, the insect organ orthologous to the kidney. Unex-
pectedly, CLN3 protein in tubules is localized to the apical domain and
also tomitochondria. Theseﬁndings alter our ideas of CLN gene function
and suggest new possibilities for the causes of NCL disease.Fig. 1. Strategy to generate YFP-CLN3 and YFP-CLN7 knock-ins. The Venus variant of YFP
was inserted after the ATG start codon of CLN7 or CLN3 to generate N-terminal fusion
proteins. For CLN3, a BAC containing the CLN3 locus and surrounding sequences was
modiﬁed by seamless recombineering to include YFP after the ATG start codon then the
BAC inserted into a landing site on chromosome II by ϕC31-mediated recombination.
For CLN7, CRISPR/Cas9-mediated homologous recombination was used to insert YFP into
the CLN7 locus. A single FLAG-tag was included at the N-terminus of YFP and a short
ﬂexible linker between YFP and CLN7. An artiﬁcial intron from the white gene was
included in the YFP sequence. Based on predicted topologies, YFP should be on the
cytosolic side for both proteins. CLN3 is likely to exist as a dimer.2. Materials and methods
2.1. Drosophila stocks and husbandry
Flies were maintained in vials on standard agar/yeast-based media
at 25 °C and 12-h light/dark cycle except during the genome editing
and recombineering procedures where semi-deﬁned medium was
used to boost egg laying (recipes available fromBloomington Stock Cen-
ter website). The control line used for all experiments was an isogenic
w1118 strain (BL 6326).2.2. CRISPR/Cas9-mediated HDR of CLN7
A gRNA was selected using ﬂy CRISPR Optimal Target Finder (tools.
ﬂycrispr.molbio.wisc.edu/targetFinder). Oligos corresponding to the
gRNA sequence were cloned into BbsI digested pCFD3 (Port et al.,
2014) and conﬁrmed by Sanger sequencing. Templates for homology-
directed repair was designed to incorporate the Drosophila codon-
optimised Venus-YFP sequence immediately 3′ of the CLN7 start
codon followed by 15 bp encoding GGAGG as a linker. 500 bp of CLN7
sequence either side of the site of the Cas9 digestion site were included
as homology arms. In one version, an artiﬁcial intron from the white
gene was incorporated into the YFP sequence to reduce the size of the
expanded YFP-containing ﬁrst exon (Fig. 1). qPCR suggested both in-
tron-containing and intron-less genes were expressed at similar levels.
Constructs were synthesized by GenScript. The gRNA andHDR template
were co-injected as supercoiled plasmids into vasa::Cas9 embryos
(BL51323) at a mixed ratio of 250:750 μg/μl respectively at the Depart-
ment of Genetics, University of Cambridge. Injectedﬂieswere crossed to
a third chromosome balancer and successful incorporation of the YFP
sequence into CG8596 detected by PCR from gDNA after mating.
Germline transmission was followed after mating by single ﬂy gDNA
PCR.
2.3. Recombineering of CLN3
The Venus variant of YFP was incorporated immediately down-
stream of the ATG start codon of the CLN3 locus by recombineering of
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step recombineering procedure was used essentially as described for
the seamless incorporation of tags into C. elegans cosmids but modiﬁed
in this case for the use of Drosophila BACs (Dolphin and Hope, 2006).
75 bp of CLN3 sequence either side of the integration site were used
for insertion of the TetR selection cassette into CLN3 and for the subse-
quent swap of TetR for YFP (Fig. 1A). Clones were validated by Sanger
sequencing and transgenic ﬂies were generated by ϕC31-mediated re-
combination into the attP40 site by BestGene. Successful transformants
were identiﬁed by PCR after mating to balancer. Standard crossing
schemes were used to generate stable stocks.2.4. Immunoﬂuorescence microscopy
Wandering third instar larvae CNS, imaginal discs, salivary glands
and Malpighian tubules were dissected in HL3.1 buffer solution (Feng
et al., 2004) then ﬁxed in 4% methanol-free EM-grade formaldehyde
(PolySciences) in HL3.1 for 30min on ice. Salivary glands andMalpighi-
an tubules samples were subsequently permeabilised for 10min and all
washing steps were performed in PBS with 0.1% Tween-20 or PBS with
0.3% Triton X-100 for all steps with CNS and discs. Samples were
blocked in 1% BSA in PBS/Tween or PBS/Triton for 30–60 min at room
temperature. Samples were incubated with primary antibodies diluted
in block overnight at 4 °C, washed several times then incubated with
the appropriate secondary antibodies in block for 2 h at room tempera-
ture. After a repeat of the washing regime, samples were mounted in
Prolong Gold (Invitrogen) or VectaShield (Vector Laboratories). Details
of antibodies used, suppliers and dilutions are provided in Supplemen-
tary materials. DNA was visualized by incubation with To-Pro 3
(Invitrogen). Images were acquired on a Zeiss LSM780 or a LSM510
Meta confocal microscopes.2.5. Immunoelectron microscopy
Immunoelectron microscopy of Malpighian tubules was carried out
after the method developed by Tokuyasu (Tokuyasu, 1986). Tubules
were ﬁxed in 4% EM-grade formaldehyde for 1 h before cryoprotection
by incubating in 2.3 M sucrose overnight. Small pieces of tubule were
mounted on cryopins and cryoﬁxed by plunging into liquid nitrogen.
The cryopins were stored under liquid nitrogen until required for
sectioning.
Sections (90 nm thick) were cut with glass knives at ‐100 °C using a
Leica cryo-ultramicrotome. Sections were collected on droplets of a
mixture of 2.3 M sucrose, 2% methyl cellulose and transferred to
pioloform-coated 150 hexagonal mesh Ni Grids. The grids were ﬂoated
on standard buffer consisting of PBS containing 1% BSA (Jackson Labora-
tories) and 0.1% sodium azide for at least 1 h. Gridswere incubatedwith
PBS containing 50 mM glycine for 15 min to block any remaining ﬁxa-
tive and thenwashed3×5mins by incubating over droplets of standard
buffer. Each gridwas then incubated on an individual droplet of primary
rabbit anti-GFP (Invitrogen) diluted 1:200 in standard buffer. Controls
were incubated on standard buffer only. Excess primary antibody was
removed by washing the grids thoroughly by placing on droplets of
standard buffer (6 droplets, 5 mins each) before incubation on droplets
of the gold-conjugated anti-rabbit antibody (Jackson labs) diluted 1:100
in standard buffer. Grids were washed as before in standard buffer be-
fore a ﬁnal wash in PBS without any additives and ﬁxed using PBS con-
taining 2% glutaraldehyde for 5 mins. The grids were then washed over
droplets of distilled water before contrasting by placing on droplets of a
solution containing nine parts 2% methylcellulose to one part 3% uranyl
acetate for 20 mins. The grids were drained by blotting against wedges
of ﬁlter paper and dried before examination. Sections were examined
using a Tecnai T12 electron microscope operated at 100 kV and images
were captured using an AMT Camera.2.6. Live imaging of Malpighian tubules
Malpighian tubules fromwandering third instar larvaewere dissect-
ed in HL3.1 containing 1:10,000 Lysotracker Red (Invitrogen) and im-
aged immediately on bridge slides on an upright Zeiss LSM510
confocalmicroscope. Laser levelswere kept low to reduce thepossibility
of photoconversion. Only the upper portions of the tubule could be im-
aged due to poor laser penetration into deeper regions.
2.7. Figure preparation
Confocal images of the larval CNS and dissected larval body wall
muscles were stitched post-acquisition on the Zeiss 780 confocal micro-
scope using Zeiss Zen software when tiling was required. Single XY im-
ages from z-stacks were exported to TIFF from Zen or Volocity software
(Perkin Elmer). z-stacks were rendered in Zen and Volocity, snapshots
taken and exported as TIFF ﬁles. Note the zoom of rendered images
may vary from the XY images and so no scale bar is included. Final ﬁg-
ures were prepared in Photoshop CS6. The resolution of the TEM mon-
tage was reduced by resampling in the “Image Size” menu to
necessarily reduce the ﬁle size.
3. Results
Identifying the expression patterns and sub-cellular localization of
NCL proteins will help elucidate their functions and further our under-
standing of cellular pathology in the NCLs. We raised antibodies to
both Drosophila CLN7 (unpublished) and CLN3 proteins (Tuxworth et
al., 2009) but both proved poorly antigenic. Our anti-CLN3 antisera
does recognize endogenous CLN3 in ﬁxed samples but only in tissues
where it is highly expressed (Fig. 6) and it shows additional non-speciﬁc
reactivity. To overcome these problems, we used two different strate-
gies to generate knock-ins: CRISPR/Cas9-mediated homology-directed
repair to make a YFP-CLN7 knock-in and seamless recombineering of a
BAC to make a YFP-CLN3 knock-in (Fig. 1 and methods). This allowed
us to use highly-speciﬁc anti-GFP antibodies to detect proteins at en-
dogenous levels in ﬁxed samples, use live imaging and, importantly,
meant the proteins were not overexpressed. This avoided a potential
confounding issue for membrane proteins whose localization may
change when overexpressed.
3.1. CLN7 and CLN3 are expressed in glia forming the blood-brain-barrier
Since pathology is largely restricted to the CNS in the NCLs, we ex-
amined expression of the CLN7 and CLN3 proteins in the mature larval
nervous system. The Drosophila larval nervous system is composed of
two major regions, the optic lobes and ventral nerve cord. Expression
proﬁling has previously indicated only low levels of expression of
CLN3 and CLN7 transcripts in the late larval nervous system (www.
ﬂyAtlas.org: Chintapalli et al., 2007; CLN7 = CG8596; CLN3 =
CG5582). We were surprised to ﬁnd that this is because both CLN7
and CLN3 proteins are largely restricted to subsets of glia in the CNS
(Figs. 2, 3 and 4) with expression only in speciﬁc neurons. Although
CLN7 is expressed predominantly within glia we do observe expression
of CLN7 in neurons of the developing visual system, both in the larval
eye disc and in the optic lobe of the brain (Figs. 2 and 4), consistent
with the early degeneration of the visual system in NCL patients.
Both proteins are expressed in the peripheral surface glia that form
the blood-brain-barrier (BBB) in insects (Limmer et al., 2014; Stork et
al., 2008). This is particularly striking for CLN7, which is expressed at
higher levels in surface glia around the entire CNS (Fig. 2). YFP-CLN7
staining overlaps with anti-Repo staining, which identiﬁes all glia with
the exception of midline glia, and does not overlapwith anti-Elav stain-
ing (post-mitotic neurons) or anti-Prospero (neural and glial precur-
sors). Optical sectioning the larval brain and ventral nerve cords from
YFP-CLN7 expressing larvae (Fig. 2. XY slice) followed by rendering of
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Fig. 3. CLN3 is expressed in surface glia in the CNS. Fixed CNS from late YFP-CLN3 larvae imagedby confocalmicroscopy. A,B: YFP-CLN3 localizationwas detectedwith anti-GFP (green) and
neuronal plasma membranes with anti-HRP (red) in the CNS from YFP-CLN3 transgenic ﬂies (A) or w1118 control ﬂies (B). YFP-CLN3 is expressed at low levels in the surface glia
surrounding the CNS. anti-GFP reactivity is absent in the control images captured and processed identically. Expression is stronger in cells over the central brain region (bracketed in
A). C: YFP-CLN3 (green) co-localizes with the pan-Repo nuclear marker anti-Repo (red) in surface glia. Higher expression of CLN3 in glia over the central brain region is indicated by
arrows. C,C': single XY optical slice and C’ 3D rendered volume. Scale bar = 100 μm.
127A. Mohammed et al. / Neurobiology of Disease 103 (2017) 123–132the sections into 3D clearly shows CLN7 ensheathing the optic lobes and
the ventral nerve cord (Fig. 2). We found YFP-CLN7was expressed in a
large number of cells with small, oblong nuclei on the apical side of
the brain that are the perineurial glia (Fig. 2C, arrowheads), but was ab-
sent from the more basal sub-perineurial glia which have characteristic
larger nuclei (Awasaki et al., 2008). CLN7 is also expressed in cells that
appear to be the channel glia in the ventral nerve chord (Fig. 2B and
D, arrow and inset box respectively).
As an alternative approach to reveal the sites of CLN7 expression we
generated a promoter fusion construct inwhich approximately 1.8 kb of
gene regulatory sequence upstreamof the CLN7 start codonwas used to
drive expression of the nuclear RedStinger reporter (Barolo et al., 2004).
RedStinger expression patternmirrors that of the YFP-CLN7 knock-in al-
though it is expressed additionally in some other glia in the CNS which
were not YFP-positive (see Supplementary Fig. S1). Both the YFP-CLN7
knock-in and CLN7::RedStinger reporter reveal that CLN7 expression is
found mostly within glia and a small subset of neurons. Surprisingly,
neither method to visualize CLN7 expression revealed any expression
in central neurons of the CNS.
YFP-CLN3 is expressed at very low levels in the CNS but high afﬁnity
anti-GFP antibodies detect expression in glia at the surface of the brain.
CLN3 expression is clearly higher in regions overlying the central brain
in comparison to the optic lobes (Fig. 3). These expression patterns cor-
relatewith transcriptome data from surface glia which showed a strong
enrichment of CLN7 (CG8596) and lower expression of CLN3 (CG5582)
(DeSalvo et al., 2014).3.2. CLN7 is expressed in the developing visual system
Early retinal pathology is common to all forms of NCL and is exhibit-
ed by a CLN7 mutant mouse (Jankowiak et al., 2016). It is interesting,
therefore, that CLN7 is expressed in the developing visual systemofDro-
sophila larvae, both in the imaginal eye discs that give rise to structures
of the eye and in the optic lobes of the CNS into which the photorecep-
tors project (Fig. 4). In the discs, YFP-CLN7 protein is seen in the Elav-
positive neurons of each ommatidium (Fig. 4A, A’) and in glia stained
with Repo (Fig. 4B, B’). In the optic lobe, YFP-CLN7 can be seen in the
lamina neurons and neuronal projections (Figs. 2A and 4B, indicated
by arrowheads in both).Fig. 2. CLN7 is expressed in subsets of glia in the CNS. Fixed CNS from late YFP-CLN7 larvae im
volumes of the optic lobe and ventral nerve chord (VNC) are shown. Note the 3D rendered im
is shown in green in each case. A, B: CLN7 is strongly expressed in the surface glia enshea
expression and the post-mitotic neuronal marker, anti-Elav (red) in lamina neurons in the o
(arrow in B.) does not co-localize with anti-Elav. C, D: The pan-glial marker anti-Repo (red) s
of the CNS in the surface glia (arrowheads in C), in one part of the optic lobe (arrows in C) and
CLN7 in the surface glia covering the surface of the CNS with each cell encircling a Repo-po
marker of neural and glial precursors. Scale bar = 50 μm.3.3. CLN7 is enriched at the post-synaptic density
We have identiﬁed roles for CLN7 in the development of the larval
neuromuscular junction (NMJ), a model for synaptic assembly and neu-
ral development (O'Hare, Mohammed, Tuxworth and Tear, unpub-
lished). Since CLN7 appears not to be expressed in the motor neurons
that innervate the NMJ (Fig. 2), we examined whether the protein is
expressed in the post-synaptic muscle tissue. Both the YFP-CLN7
knock-in and the CLN7::RedStinger reporter show expression in all
body wall muscles in wandering third instar larvae (Fig. 5A, D), in seg-
mentally repeated clusters of oenocytes (Fig. 5A and circled in Fig. 5C)
and in the overlying epithelial cells. Importantly, YFP-CLN7 is concen-
trated at the NMJ in each of the muscles forming clusters around each
swelling (bouton) of the pre-synaptic membrane (Fig. 5B, B’). The
anti-GFP staining is clearly separable from the pre-synaptic membrane
visualized with anti-HRP (red in Fig. 5B, B’). This is true for both the
type Ib and Is junctions and indicates recruitment to, or concentration
at, the post-synaptic density.
3.4. CLN3 localizes to the apical domain of tubules
FlyAtlas (Chintapalli et al., 2007) indicates high levels of CLN3 tran-
scription inMalpighian tubules, the insect organ orthologous to the kid-
ney. We ﬁxed and stained tubules from YFP-CLN3 expressing animals
with anti-GFP and wild-type tubules with anti-CLN3 to visualize CLN3
expression (Fig. 6A–E,). In both cases we saw strong expression of
CLN3, as predicted by the expression proﬁling, which was absent in
CLN3 homozygous mutant tubules (Fig. 6F). However, we were sur-
prised to ﬁnd that the majority of CLN3 protein localizes to the extreme
apical domain that forms the lumen of the tubule (Fig. 6A–E). An unre-
lated GFP protein trap inserted in the Vha55 gene encoding a vacuolar
H+ ATPase does not localize to the apical domain and is clearly separa-
ble from CLN3 protein (Fig. 6C). Tubules were co-stained with antibod-
ies to the Na+/K+ ATPase transporter that resides in the basal
membrane. The apical CLN3 and basal Na+/K+ ATPasewere clearly sep-
arated spatially (Fig. 6E). The Malpighian tubules have a thick network
of actin-richmicrovilli protruding into the lumen. Interestingly, staining
YFP-CLN3 tubules with anti-GFP and phalloidin to visualize the F-actin
indicates that CLN3 is found more apical than the predominant F-actin
band: the two signals are clearly resolvable by standard confocalaged by confocal microscopy. Single XY optical slices and the corresponding 3D rendered
ages have been rotated in some instances. YFP-CLN7 localization detected with anti-GFP
thing the CNS with some expression in the optic lobe. There is overlap between CLN7
ptic lobe (enlargement shown in box in A). Strong expression in the midline of the VNC
hows YFP-CLN7 co-localization with Repo-positive nuclei around the extreme periphery
in channel glia in the VNC (enlargement shown in box in D). The 3D renders show YFP-
sitive glial nucleus. E,F. No overlap between YFP-CLN7 localization and anti-Prospero, a
Fig. 4. CLN7 is expressed in neurons and glia in the developing visual system. Fixed eye imaginal discs from YFP-CLN7 larvae stained with anti-GFP (green). A,A’: anti-Elav (red) marks
neuronal photoreceptors. B,B’ anti-Repo (red) marks glia (B,B’). A and B show single XY sections; A’ and B’ show 3D renders of z-stacks. Note the expression of CLN7 in both neurons
and glia and the distribution of CLN7 along photoreceptor projects into the visual centres of the brain in B and B’. Scale bar = 50 μm.
128 A. Mohammed et al. / Neurobiology of Disease 103 (2017) 123–132microscopy (Fig. 6D). This suggested a potential localization of CLN3 to
the tips of the microvilli. The low-afﬁnity anti-CLN3 shows some non-
speciﬁc reactivity hence, only the strongest CLN3 signal can be detected
unambiguously. However, the highly speciﬁc anti-GFP reveals some ad-
ditional CLN3 protein in tubules, especially in small foci (Fig. 6B, D). To
gain further insight into this potential additional localization, we dis-
sected YFP-CLN3 expressing tubules, stained then brieﬂy with the vital
low pH vesicle marker, lysotracker, and imaged them by confocal mi-
croscopy without ﬁxation. Single optical sections taken near the upper
surface of the tubules reveals large, autoﬂuorescent vesicles positive
for lysotracker that are likely to be lysosomes (Fig. 6G, marked with as-
terisks; compare also with TEM in Fig. 7 and other reports of the ultra-
structure of lysosomes of insect Malpighian tubules (Pal and Kumar,
2013)). Again, small foci of YFP-CLN3were visible (Fig. 6G, circled) like-
ly corresponding to the small foci seen in ﬁxed samples (cf. Fig. 6B and
D). Additionally, some YFP-CLN3 appeared to be localized to the mem-
brane of the lysotracker-positive vesicles (Fig. 6H and H’), consistent
with the multi-span transmembrane nature of the CLN3 protein.
Salivary glands in Drosophila are also single cell-thick tubules. Inter-
estingly, the anti-CLN3 antibody also reveals strong localization of en-
dogenous CLN3 to the apical side of salivary gland cells adjacent to theFig. 5. CLN7 is recruited to the post-synaptic density at the neuromuscular junction. Late-s
innervations. A: CLN7 (anti-GFP, green) is expressed in all body wall muscles, oenoctyes and
at all neuromuscular junctions. YFP-CLN7 is detected with anti-GFP (green) and neuronal m
recruited to both type Is and Ib neuromuscular junctions (arrows). Two type Ib boutons are fu
C) and all body-wall muscles (D) is conﬁrmed with the nuclear RedStinger promoter fusion (
C); 100 μm (B and D); 50 μm (B’).central lumen (Fig. 6K). Moreover, a YFP-tagged CLN3 protein remains
predominantly localized adjacent to the lumen even under overexpres-
sion conditions (Fig. 6L, L’).
3.5. CLN3 localizes to microvilli, mitochondria and lysosomes in tubules
To gain increased resolution of this intracellular expression we used
immuno-electron microscopy of frozen sections of Malpighian tubules.
The microvilli in insect Malpighian tubules are much longer than verte-
brate microvilli and possess mitochondria along their length (Ryerse,
1979). Mitochondria are also present at the base of microvilli with
large, irregularly-shaped lysosomes present more basally correspond-
ing to the large lysotracker-positive vesicles seen in the live imaging
(Fig. 6G,H). Using anti-GFP in YFP-CLN3 tubules with a gold-labelled
secondary antibody, we detected CLN3 along microvilli, usually close
to themembrane (Fig. 7D,E,J). Wewere surprised to see CLN3 localized
within mitochondria, most clearly in the mitochondrial-rich area at the
base of microvilli (Fig. 7F,G,I,J). Since we used a primary and secondary
antibody to detect the CLN3 protein, the location of the YFP molecule
could be anywhere within an approximately 20 nm radius of each
gold particle but despite this, several gold particles were comfortablytage YFP-CLN7 larvae were dissected and ﬁxed to observe the body-wall muscles and
in the overlying epidermis. B: YFP-CLN7 protein is recruited to the post-synaptic density
embranes with anti-HRP (red). Muscle IV is boxed. B’ Higher magniﬁcation of B. CLN7 is
rther magniﬁed in the inset box. C, D: Strong expression of CLN7 in oenocytes (circled in
red). F-actin is visualized with Alexa-488 phalloidin (green). Scale bar = 250 μm (A and
Fig. 6. CLN3 in Malpighian tubules localizes to the apical domain. CLN3 is highly expressed in Malpighian tubules (the insect excretory and detoxiﬁcation organ). A: low magniﬁcation
image of the junction between gut and tubules (arrowheads indicate each tubule) from a YFP-CLN3 larva stained to visualize septate junctions (anti-DLG, red), DNA (blue) and YFP-
CLN3 expression (anti-GFP, green). Note the localization of YFP-CLN3 to the convoluted lumen of the tubules. B: 3D render of a z-stack through a YFP-CLN3 tubule stained with anti-
GFP to show the localization of YFP-CLN3 to the lumen. C: single XY slice through tubule from a v-H+ ATPase GFP protein trap line stained with anti-CLN3 (green) and anti-GFP (red).
v-H+ ATPase is excluded from the apical domain. This conﬁrms the apical localization of endogenous CLN3 and demonstrates that the YFP fusion to CLN3 does not affect localization.
D: a co-stain of anti-GFP (green, D) with Alexa-546 phalloidin to visualize F-actin in tubules (D’, red). The merged image (D”) regions shows YFP-CLN3 more apical than the band of F-
actin running underneath and parallel to the lumen. E: anti-CLN3 staining of wild-type tubules conﬁrms the localization of endogenous CLN3 protein to the apical domain abutting the
lumen. Tubules are triple-stained with anti-CLN3 (green), anti-Na+/K+ ATPase (red) and phalloidin (blue). E’ and E” show a single XZ optical section and a 3D render of the volume of
the same tubule as in E. For clarity, F-actin is not shown. Note the clear separation between apical (luminal) CLN3 and basal Na+/K+ ATPase. F: tubule from a CLN3−/− null larva
stained and imaged identically to (E) to show the speciﬁcity of the anti-CLN3 antibody. G&H: Live imaging of YFP-CLN3 (green) in tubules counterstained with lysotracker (red) to
mark low-pH endosomes and lysosomes. G: A single XY optical section from the upper part of a tubule reveals small foci of YFP-CLN3 present in unidentiﬁed vesicles (circled). The
large lysotracker-positive vesicles are autoﬂuorescent (asterisks). H, H’: a single XY section (H) from the upper part of a tubule shows YFP-CLN3 apparently localized to the membrane
of some lysotracker-positive vesicles (arrows; boxed vesicle is enlarged in inset). The accompanying 3D–rendered image shows the membrane localization more clearly (arrows;
boxed vesicle is enlarged in inset). Note the convoluted lumen with high levels of YFP-CLN3 also enters the optical sections of (G) and (H) in places (arrowheads). I&J: CLN7 is also
expressed in tubules. A single XY optical slice (I) and a 3D render (I’) of a YFP-CLN7 tubule stained with anti-GFP (green) and anti-Na+/K+ ATPase (red) reveal CLN7 is largely
localized in large, peripheral vesicles likely to be lysosomes. J: expression of CLN7 only in the principal cells of the tubule is conﬁrmed with the nuclear RedStinger promoter fusion
(red). Arrows point to stellate cells not expressing YFP-CLN7. K&L: CLN3 is also localized to the apical domain of salivary glands, which are also single cell tubules. K: anti-CLN3
staining (green) from a larva expressing YFP-Rab5 as a counterstain (red, detected with anti-GFP). L&L’: YFP-tagged CLN3 expressed from a UAS-transgene. Despite overexpression,
YFP-CLN3 remains apical (green). LAMP-HRP and DNA stains show morphology (red and blue). L’ is a higher magniﬁcation image of a central section of L. Scale bars = 5 μm (A-J); 20
μm (I); 50 μm (L&L’).
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cence seen in the lumen of tubules by live imaging corresponds to YFP-
CLN3 accumulation in microvilli and the small more basally located foci
to YFP-CLN3 in mitochondria. We also detected occasional localization
of YFP-CLN3 to the large vacuolar organelles, which we deduce arelysosomes based on the large, lysotracker-positive vesicles seen in the
live imaging (Fig. 6 G,H) and on their highly similar appearance to lyso-
somes in other ultrastructural studies of insect Malpighian tubules (Pal
and Kumar, 2013). The lysosomes include one apparently containing a
mitochondrion, possibly during mitophagy (Fig. 7J).
Fig. 7. ImmunoEM localizes CLN3 to microvilli, mitochondria and lysosomes. ImmunoEM staining of YFP-CLN3 transgenic tubules from late larvae were stained with rabbit anti-GFP and
gold-conjugated anti-rabbit antibodies. A–C were stained without primary antibody and no gold particles are visible, demonstrating the speciﬁcity of the secondary antibody. A–C: The
morphology of control tubules reveal important features of the insect Malpighian tubule. A,B: Microvilli (MV) protrude into the tubule lumen; many mitochondria are visible
immediately below the microvilli (M); large vacuoles reported previously to be lysosomes are visible (L; Pal and Kumar, 2013). C: Numerous mitochondria are present within and at
the base of microvilli (arrows). D&E: Gold particles corresponding to YFP-CLN3 are localized to microvilli, likely in the membrane (white circles). F: A gold particle within a
mitochondrion (circle, magniﬁed in F’). G–I: Higher magniﬁcation examples gold particles found in microvilli (G) and within mitochondria (H&I). J&K: Gold particles within large
lysosome-like vesicles (black circles). Note also the presence of a mitochondrion within a lysosome (J, large black circle). Scale bars = 2 μm (A,B); 500 nm (D,J,K); 100 nm (E–I),
50 nm (F’).
130 A. Mohammed et al. / Neurobiology of Disease 103 (2017) 123–132CLN7 is also expressed in the principal cells of Malpighian tubules
where it is predominantly localized to large peripheral vesicles likely
to be lysosomes (Fig. 6I). The RedStinger promoter fusion indicates
CLN7 is not expressed in stellate cells (Fig. 6J, CLN7+ principal cell nu-
clei indicated with circles and CLN7− stellate cells nuclei with arrows).
4. Discussion
We have used genome engineering and recombineering to generate
knock-in constructs to generate YFP tagged CLN7 and CLN3 proteins
expressed from their endogenous loci.We have used these lines to over-
come the poor antigenicity of the CLN7 and CLN3 proteins and allow the
investigation of their cellular expression and sub-cellular localization.
Surprisingly, we found that both CLN7 and CLN3 have restricted expres-
sion in the CNS: CLN7 is expressed in neurons in the developing visual
system, but not widely in neurons elsewhere, and CLN3 is absent from
neurons. Instead, in the CNS both CLN7 and CLN3 are primarily glial pro-
teins. Unexpectedly, we ﬁnd that CLN3 is additionally localized at the
apical domain of tubules and in mitochondria.
There is always the possibility that a ﬂuorescent fusion protein
might not fold correctly, thus affecting its localization. We believe this
to be unlikely in this study since YFP-CLN3 localization matches the en-
dogenous CLN3 proteinwhere we are able to visualize it.We attempted
to reduce the possibility of mis-folding as far as possible by inserting
YFP at the extreme N-terminus of both CLN7 and CLN3 coding se-
quences. Many groups have used N-terminal fusions of GFP to CLN3 in
a variety of models without retention of the protein in the ER (Codlin
and Mole, 2009; Huber et al., 2014; Oetjen et al., 2016) and GFP-CLN3
is functional in both yeast (Codlin and Mole, 2009) and Dictyostelium(Huber et al., 2014). In contrast, we and others have shown that trun-
cated forms of CLN3—or adding epitope tags or GFP to the C-
terminus—does lead to ER retention and a very different sub-cellular
staining pattern than that we see here (example studies include
Haskell et al., 1999; Jarvela et al., 1999; Tuxworth et al., 2009). In the
case of YFP-CLN7,we have no antibody to detect endogenous CLN7 pro-
tein and there have been few comparable studies. However, we can res-
cue the neurodevelopmental phenotype of CLN7mutant animals by re-
expressing a YFP-CLN7 construct (O'Hare, Mohammed, Tuxworth and
Tear, in prep). This indicates YFP-CLN7 is functional so must be folded
and localized correctly.4.1. Expression of CLN7 and CLN3 in glia
We ﬁnd that CLN7 and CLN3 are largely restricted to glia in the Dro-
sophila CNS but this contrasts with the mammalian CNS where both
genes are also expressed widely. Indeed, CLN7 transcripts are several-
fold higher in neurons than in glia in the rat CNS (Shariﬁ et al., 2010).
One possibility is Drosophila reﬂects an ancestral expression pattern in
glia that has been expanded to expression throughout the CNS in verte-
brates. Autoﬂuorescent storage material accumulates widely in CNS of
human NCL patients but is not detectable in mutant CLN3 or CLN7 ﬂies
(O'Hare and Tuxworth, unpublished) consistent with the restricted ex-
pression of the genes. It is notable that activation of glial cells is the ear-
liest detectable event in animal models of various NCLs (Cooper et al.,
2015; Kay et al., 2006; Oswald et al., 2005; Pontikis et al., 2004) but
the triggers for glia activation in NCL and the roles that glial cells may
play in the disease process are not well understood. Studying CLN3
131A. Mohammed et al. / Neurobiology of Disease 103 (2017) 123–132and CLN7 function in glia in Drosophilamay give some insight into these
early events in NCL pathology.
We could not detect CLN3 expression in the visual system at the
third instar larval stage of development but CLN7 is expressed in neu-
rons and glia at this stage. Atrophy of the visual system is a common fea-
ture of all of the childhood-onset forms of NCL and is seen in CLN7
mutant mice (Jankowiak et al., 2016); again, this may reﬂect a con-
served ancestral role for CLN7 and it will be interesting to determine
whether CLN7mutant ﬂies suffer similar visual pathology.
4.2. Potential functions for CLN7 in the Blood-Brain-Barrier
We found CLN7 to be primarily expressed in the surface glia, which
form the BBB in insects (Stork et al., 2008). The surface glia comprise
two different types: the apical perineurial glia, which express numerous
solute transporters, and the underlying sub-perineurial glia, which form
occlusive tight-junctions, analogous to the endothelial tight junctions in
the vertebrate BBB. CLN7 appears to be restricted to the apical
perineurial glia, in keepingwith its likely role as a solute transporter. In-
terestingly, YFP-CLN7 appears to be localized predominantly at, or near
the plasmamembrane in these glia. We did not expect to see this local-
ization at the outset of the study because human and mouse CLN7 are
predominantly late-endosomal and lysosomal proteins in cultured
cells (Shariﬁ et al., 2010; Steenhuis et al., 2010) and has been identiﬁed
in lysosomal membranes by proteomics (Chapel et al., 2013). However,
CLN7 in Malpighian tubule principal cells was predominantly localized
in large vesicles likely to be lysosomes. Both the surface glia and Malpi-
ghian tubules regulate solute transport—across the BBB and gut
respectively—so it seems likely that CLN7 contributes to solute transport
in both cell types. One possibility is that the transporters are localized
differently in the glia and the tubules or possibly that the thin, stretched
nature of the perineurial cells falsely gives the impression of plasma
membrane localization.
Both principal and stellate cells express numerous solute trans-
porters for osmoregulation, excretion and detoxiﬁcation but the ab-
sence of CLN7 from stellate cells indicates it is unlikely to be involved
in chloride transport. Interestingly, the surface glia also contribute to
regulation of organismal growth indirectly through secretion of a solu-
ble insulin receptor antagonist, SDR (Okamoto et al., 2013). Reduced ex-
pression of SDR results in increased insulin signalling and increased
growth of the ﬂy, a phenotype that is also present in CLN7 mutants
(O'Hare, Mohammed, Tuxworth and Tear, unpublished) so it will be of
interest to determine whether SDR secretion is affected by CLN7 loss.
4.3. CLN3 and other NCL gene expression in glia
CLN3 is also expressed in surface glia but the expression is low and is
not uniform in all surface glia of the larval CNS (Fig. 3). Expression ap-
pears to be stronger in the region overlying the central brain (Fig. 3,
bracketed section) and lower or absent in glia overlying the optic
lobes. Transcriptome proﬁling of surface glia conﬁrms CLN3 expression
and while it is not clear what role CLN3might play in these glia, it is in-
teresting to note that disruption to the BBB has been reported in human
Juvenile NCL and in CLN3mutantmice and that cultured CLN3−/− endo-
thelial cells show disruption to membrane microdomains and trafﬁck-
ing (Tecedor et al., 2013).
4.4. CLN3 localization to the apical domains of tubules
CLN3 is widely reported to be a lysosomal protein. However, the lack
of high-afﬁnity antibodies for endogenous CLN3 means almost all stud-
ies have relied on overexpression of epitope-tagged proteins or ﬂuores-
cent fusion proteins; additionally, most studies have used cultured cells
rather than observations in vivo. However, there is plausible evidence
that endogenous CLN3 might reside in variable locations in different
cell types. In yeast, the endogenous CLN3 locus has been tagged byrecombination which revealed that the protein appears to reside in
the Golgi when expressed at endogenous levels (Kama et al., 2011); in
primary neurons, overexpressed CLN3 appears to be present in synaptic
vesicles in addition to lysosomes (Kyttala et al., 2004; Luiro et al., 2001);
in themouse retina one of the few studies to visualize endogenous CLN3
revealed localization to mitochondria in Müller glial cells and in photo-
receptor inner segments (Katz et al., 1997). It is of interest, therefore,
that we ﬁnd both the endogenous Drosophila CLN3 and a YFP-CLN3 fu-
sion expressed at endogenous levels are found in the apical domain of
tubular structures i.e. exposed to the lumen, suggesting a possible role
in secretion or transport. Moreover, we see also some CLN3 present in
mitochondria, in agreement with expression seen in the mouse retina
(Katz et al., 1997). The β-galactosidase reporter mouse of CLN3 expres-
sion showed unexpected, strong expression from early stages of embry-
onic development in the endothelia of the brain (Eliason et al., 2007). It
was unclear why CLN3 is expressed there so strongly but follow-up
studies from the Davidson laboratory have shown CLN3−/− endothelia
have disrupted membrane microdomains, altered drug efﬂux across
the epithelium and abnormal volume regulation (Tecedor et al., 2013).
Cells expressing a CLN3 transgene after viral transduction reveal the
CLN3 protein is localized to the trans Golgi network, which regulates
much of the trafﬁcking in polarized cells. However, the cells in that
study were not polarized. Could the localization of CLN3 be different in
polarised epithelia? CLN3 is strongly expressed in renal tubules in the
mouse and CLN3 transcription is regulated by osmolality (Getty et al.,
2013; Stein et al., 2010); here we show that CLN3 is expressed inMalpi-
ghian tubules that are orthologous to the mammalian kidney. We have
not asked if CLN3 is similarly regulated by salt in ﬂy tubules nor havewe
interrogated tubule function in adult ﬂies lacking CLN3 (or CLN7). How-
ever, it is potentially signiﬁcant that CLN3 in Dictyostelium is predomi-
nantly resident in the membrane of the contractile vacuole, an
osmoregulatory organelle (Huber et al., 2014). Taken together, these
ﬁndings suggest a role for CLN3 in solute transport and osmoregulation.
If the localization of the protein we see in the ﬂy is conserved in polar-
ized tubules of mammals, such as the brain endothelia, it will change
our view of CLN3 protein function and the underlying cell biology of
the disease.4.5. CLN3 in mitochondria
Our electron microscopy study found CLN3 in multiple locations in
the Malpighian tubules: in the microvilli, in mitochondria and in lyso-
some-like vesicles. The study that localized CLN3 to mitochondria in
themouse retina (Katz et al., 1997) has not, to our knowledge, been re-
peated. We are not clear whether the antibody used in that study does
not recognize endogenous CLN3 in other tissues with lower expression
levels - or whether it subsequently was shown to be non-speciﬁc by
others. Either way, it is intriguing that we also see some mitochondrial
localization of CLN3 inDrosophila given that an in vitro TAP-tag puriﬁca-
tion study identiﬁed CLN3 in complexwith severalmitochondrial trans-
porters and inner membrane proteins in neuroblastoma cells (Scifo et
al., 2013). How CLN3 would be imported into mitochondria is unclear.
No homologue of CLN3 contains a canonical positively-charged mito-
chondrial import leader sequence at the N-terminus of the protein.
However, only 70% of mitochondrial proteins are imported by this
method and other sequences or motifs regulating import are less well
described (reviewed in Chacinska et al., 2009). If a mitochondrial local-
ization for CLN3 is conﬁrmed in vivo in other mammalian tissues, it will
cause us to reconsider CLN3 function.
This study highlights the power of gene editing technology in facili-
tating protein localization studies. We have used two differentmethods
to study CLN3 and CLN7 that have proved difﬁcult to study with anti-
bodies. By removing the possibility of overexpression artefacts we
have identiﬁed surprising localization for both proteins and raised
new questions about the cell biology of the NCLs.
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• Knock-in strategies inDrosophilawere used to generate YFP-CLN7 and
YFP-CLN3 fusions to assess in vivo localization without overexpres-
sion.
• YFP-CLN7 and YFP-CLN3 show restricted expression in the CNS. Ex-
pression is largely restricted to the surface glia that form the blood
brain barrier. CLN7 is also expressed in neurons and glia in the devel-
oping visual system.
• CLN7 and CLN3 are expressed in the Malpighian tubules. CLN3 is
strongly enriched at the apical domain adjacent to the lumen. Some
CLN3 is also detected in mitochondria.
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